Compare RVSB & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | VSTM |
|---|---|---|
| Founded | 1923 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 731.8M |
| IPO Year | 1997 | 2011 |
| Metric | RVSB | VSTM |
|---|---|---|
| Price | $5.72 | $7.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $16.50 |
| AVG Volume (30 Days) | 51.6K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $53.63 | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | $70.38 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $4.81 | $3.43 |
| 52 Week High | $6.22 | $10.82 |
| Indicator | RVSB | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 72.85 | 52.86 |
| Support Level | $5.23 | $6.68 |
| Resistance Level | $5.72 | $7.86 |
| Average True Range (ATR) | 0.10 | 0.41 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 81.54 | 26.38 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.